ANNUAL REPORT 2007 | 2008 - Gimv
ANNUAL REPORT 2007 | 2008 - Gimv
ANNUAL REPORT 2007 | 2008 - Gimv
Create successful ePaper yourself
Turn your PDF publications into a flip-book with our unique Google optimized e-Paper software.
PORTFOLIO<br />
AND EQUITY<br />
EQUITY (LIMITED CONSOLIDATION)<br />
Financial assets valued at fair value through P&L (I) 737 935<br />
of which listed shareholdings<br />
Company Bloombergsymbol<br />
Shareholding<br />
in %<br />
Shareholding in<br />
no. of shares<br />
Bid price in local<br />
currency<br />
Value<br />
(in EUR 000)<br />
Ablynx 1 ABLX BB 10.2% 3 703 483 5.70 20 751<br />
Alfacam ALFA BB 3.2% 255 282 12.30 3 140<br />
Avalon Pharmaceuticals AVRX US 5.3% 891 607 2.26 1 274<br />
Barco BAR BB 9.9% 1 249 921 45.35 56 684<br />
Evotec EVT GR 0.5% 360 238 1.70 612<br />
Galapagos GLPG BB 0.4% 87 940 5.91 520<br />
Innate Pharma IPH FP 7.6% 1 925 020 2.03 3 908<br />
LivePerson LPSN US 1.3% 644 323 3.05 1 243<br />
Memory Pharmaceuticals MEMY US 1.4% 1 051 628 0.48 319<br />
Metris MTRS BB 4.5% 563 261 8.95 5 041<br />
Metris warrants - - 425 890 1.64 698<br />
Santhera Pharmaceuticals SANN SW 5.0% 156 192 69.10 6 858<br />
Telenet TNET BB 1.3% 1 415 344 14.00 19 815<br />
Thrombogenics THR BB 0.2% 40 000 7.30 292<br />
Torreypines Therapeutics TPTX US 11.0% 1 738 179 1.36 1 495<br />
Total listed shareholdings 122 650<br />
Loans to companies in the investment portfolio (II) 110 209<br />
Total portfolio (I + II) 848 144<br />
Other assets net of commitments (III) 501 120<br />
Minority interests (IV) 21 710<br />
Equity (attributable to equity holders of the parent company) (I + II + III - IV) 1 327 554<br />
1 Value of Ablynx shares adjusted before lock-up period
Change language